Get the Stockscreener App
2.90
0.68%
-0.02
After Hours:
2.86
-0.04
-1.38%
Puma Biotechnology Inc stock is traded at $2.90, with a volume of 367.24K.
It is down -0.68% in the last 24 hours and down -14.45% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$2.92
Open:
$2.81
24h Volume:
367.24K
Relative Volume:
0.75
Market Cap:
$142.35M
Revenue:
$230.47M
Net Income/Loss:
$30.28M
P/E Ratio:
4.7541
EPS:
0.61
Net Cash Flow:
$38.86M
1W Performance:
-7.64%
1M Performance:
-14.45%
6M Performance:
+9.43%
1Y Performance:
-47.37%
1-Day Range:
$2.7801
$2.94
1-Week Range:
$2.7801
$3.14
52-Week Range:
$2.225
$6.055
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
2.90 | 142.35M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
Puma Biotech Expands Team: New Hires Receive Strategic Stock Compensation Package - Stock Titan
Further weakness as Puma Biotechnology (NASDAQ:PBYI) drops 11% this week, taking five-year losses to 55% - simplywall.st
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 - BioSpace
Groundbreaking Clinical Trial: Neratinib's Novel Combination Approach Targets HER2 Tumors - Stock Titan
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why - Nasdaq
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - MSN
Why Investors Are Buzzing About Puma Biotechnology’s Earnings: Unpacking the Details - procarsrl.com.ar
Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now - MSN
Checking in on Puma Biotechnology Inc (PBYI) after recent insiders movement - Knox Daily
Rhumbline Advisers Lowers Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26% - Simply Wall St
Puma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.com - Armenian Reporter
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by StockNews.com - Defense World
We Think Puma Biotechnology's (NASDAQ:PBYI) Healthy Earnings Might Be Conservative - Yahoo Finance
Puma Biotech grants stock award to new hire By Investing.com - Investing.com Australia
Puma Biotechnology, Inc. to Host Earnings Call - ACCESS Newswire
Puma Biotechnology to Present at Barclays 27th Annual Global Healthcare Conference - BioSpace
Puma Biotech grants stock award to new hire - Investing.com India
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference - BioSpace
Can Puma Biotechnology's Conference Presentation Signal New Growth Opportunities? - StockTitan
Puma Biotechnology’s Earnings Call: Mixed Sentiments and Future Outlook - MSN
Puma Biotechnology’s (PBYI) Buy Rating Reiterated at HC Wainwright - Defense World
Results: Puma Biotechnology, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates - Nasdaq
Puma Biotechnology: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St
Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results - sharewise
Puma Biotechnology Reports Strong Earnings Growth in 2024 - TipRanks
Puma Biotech: Q4 Earnings Snapshot - CTPost
Puma Biotechnology: Hold Rating Amidst Flat Sales Growth and Uncertain Drug Prospects - TipRanks
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Puma Biotech Q4 2024 beats earnings expectations By Investing.com - Investing.com South Africa
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Earnings call transcript: Puma Biotech Q4 2024 beats earnings expectations - Investing.com
Puma Biotech stock rises as Q4 earnings surpass expectations By Investing.com - Investing.com Canada
Puma Biotech stock rises as Q4 earnings surpass expectations - Investing.com
Puma Biotechnology Boosts Profits 57% While Revenue Dips: What's Behind This Earnings Paradox? - StockTitan
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference - BioSpace
Puma Biotechnology Reveals Corporate Strategy at Major Healthcare ConferenceWhat Will CEO Disclose? - StockTitan
Puma Biotechnology Inc expected to post earnings of 10 cents a shareEarnings Preview - TradingView
Investors in Puma Biotechnology (NASDAQ:PBYI) have unfortunately lost 73% over the last five years - Yahoo Finance
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Puma Biotechnology Inc Stock (PBYI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ludwig Jeffrey Jerome | Chief Commercial Officer |
Jan 02 '25 |
Sale |
3.15 |
9,437 |
29,743 |
108,951 |
| HUNT DOUGLAS M | See Remarks |
Jan 02 '25 |
Sale |
3.15 |
8,633 |
27,209 |
124,594 |
| AUERBACH ALAN H | President and CEO |
Jan 02 '25 |
Sale |
3.15 |
33,841 |
106,657 |
7,029,674 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):